Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
High-Dose Rituximab vs Standard-Dose Rituximab + CVP in Relapsed/Refractory Chronic ITP
NCT00161564Phase 2Withdrawn
- Sponsor
- Weill Cornell Medicine
- Start
- Feb 2004
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised trial of rituximab in immune thrombocytopenia (ITP) (2 arms), sponsored by Weill Cornell Medicine. Primary endpoints: Overall Response Rate at 16 weeks and Adverse Events. Planned start Feb 2004; status: withdrawn.
02
Drugs
rituximab
03
Conditions
immune thrombocytopenia (ITP)
Beyond the preview
Go deeper on NCT00161564.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00161564.